

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF ENROLLMENT OF
THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF
TRD208 “NON-OPIOID MULTI-TARGET MULTI-MODAL ANALGESIC”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the enrollment of the first patient in the Phase I clinical trial conducted in China for TRD208, a National Class 1 innovative drug independently developed by the Group, has been successfully completed. TRD208 is a First-in-Class, non-opioid, multi-target, multi-modal analgesic, which is expected to become a blockbuster innovative drug in the field of acute pain management.

With its unique multi-target mechanism of action, TRD208 is capable of blocking multiple pain-related transmission pathways in the central nervous system, including NaV1.7, NaV1.8 and others. It also exhibits peripheral anti-inflammatory and analgesic effects as those characterized by non-steroidal anti-inflammatory drugs (NSAIDs). In addition, TRD208 can suppress central sensitization, and is expected to reduce the risk of neuropathic pain induced by acute pain.

As indicated by the pre-clinical data, TRD208 demonstrates rapid onset, potent analgesic effects, and prolonged duration of action in the model of postoperative pain. As a non-opioid drug with multi-target synergistic effects, TRD208 is expected to be the first single agent to achieve multi-modal analgesic effects, which may potentially replace current mainstream combination therapies. This novel agent addresses clinical needs throughout the analgesic process and offers key advantages, including simplified treatment regimens, improved patient compliance, and avoidance of opioid-related addiction and dependence risks.

Surgery/analgesia is one of the key therapeutic areas of the Group. Currently, a diversified portfolio of marketed products has been established, including Meloxicam Injection (II) (普坦寧®), Flurbiprofen Cataplasms (澤普思®/得百安®), Lidocaine Cataplasms (得百寧®), Loxoprofen Sodium Cataplasms (得舒平®), Limaprost Tablets (凱立通®), etc. The Group focuses on the development of innovative non-opioid targeted drugs, in order to precisely address the substantial unmet clinical needs within the field of analgesia. In particular, TRD205 is the first AT2R antagonist to enter the Phase II clinical trial globally. The Group is committed to expediting the research and development of innovative analgesic therapies, aiming to deliver novel treatment options with significant clinical value.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 1 December 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.